Inovio Pharmaceuticals, Inc.
Cancer vaccines targeting PRAME and uses thereof
Last updated:
Abstract:
Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated consensus PRAME antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a mutated consensus PRAME antigen are disclosed. Methods of treating a subject with a PRAME-expressing tumor and methods of preventing a PRAME-expressing tumor are disclosed. Mutated consensus PRAME antigen is disclosed.
Status:
Grant
Type:
Utility
Filling date:
13 Dec 2018
Issue date:
24 May 2022